The Kansas City Bioscience Authority (KBA) has launched a collaborative partnership of more than 90 contract research organizations (CROs) to help the region compete in the pharmaceutical and medical device industries. BioResearch Central will help promote the Greater Kansas City region as a destination for pharmaceutical R&D at a time when drug companies are increasingly looking overseas for their contract research needs. The announcement follows the release of a KBA commissioned study that suggests pharmaceutical contract research is a $90-$105 billion industry in the U.S., much larger than previous estimates.
BioResearch Central will attempt to link the Kansas City region's CROs and related service providers to build a nationally-recognized research network, providing a wide spectrum of services for pharmaceutical and biotechnology companies. The CROs involved in the network provide a wide spectrum of research services, including drug discovery, toxicology, bioanalysis, clinical trials, and regulatory and commercial support. These companies currently generate almost $1 billion in annual revenue and employ more than 9,000 people in the Greater Kansas City region. The new network will help accelerate and improve the product development process by finding the right providers for specific research. It will also facilitate knowledge transfer and connections between the partner organizations.
To read the full, original article click on this link: SSTI - SSTI Weekly Digest
